COMP <GO>
GLSI vs LYEL // GROSS PROFIT MARGIN
Greenwich LifeSciences Inc. (NASDAQ) VS. Lyell Immunopharma Inc. (NASDAQ) • 15-METRIC TALLY: GLSI 1
— LYEL 2
■ METRIC PARITY
LAST: $19.00 (+3.77%) • MKT CAP: $278.9M
gross-margins
—
LAST: $11.31 (+3.43%) • MKT CAP: $277.0M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GLSI VS. LYEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GLSI | LYEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.55% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -41.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | LYEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 61.4 | -8.36 | LYEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $278.9M | $277.0M | $1.9M | GLSI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GLSI REV | LYEL REV | GLSI GROSS % | LYEL GROSS % | GLSI FCF | LYEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $36.0K | — | — | -$9.9M | -$150.8M |
| FY 2024 | $0 | $61.0K | — | — | -$7.3M | -$162.9M |
| FY 2023 | $0 | $130.0K | — | — | -$6.5M | -$163.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GLSI // BETA —
LYEL // BETA —